Event Memory
event memory
Enhancing Real-World Event Memory
Memory is essential for shaping how we interpret the world, plan for the future, and understand ourselves, yet effective cognitive interventions for real-world episodic memory loss remain scarce. This talk introduces HippoCamera, a smartphone-based intervention inspired by how the brain supports memory, designed to enhance real-world episodic recollection by replaying high-fidelity autobiographical cues. It will showcase how our approach improves memory, mood, and hippocampal activity while uncovering links between memory distinctiveness, well-being, and the perception of time.
Computational Principles of Event Memory
Our ability to understand ongoing events depends critically on general knowledge about how different kinds of situations work (schemas), and also on recollection of specific instances of these situations that we have previously experienced (episodic memory). The consensus around this general view masks deep questions about how these two memory systems interact to support event understanding: How do we build our library of schemas? and how exactly do we use episodic memory in the service of event understanding? Given rich, continuous inputs, when do we store and retrieve episodic memory “snapshots”, and how are they organized so as to ensure that we can retrieve the right snapshots at the right time? I will develop predictions about how these processes work using memory augmented neural networks (i.e., neural networks that learn how to use episodic memory in the service of task performance), and I will present results from relevant fMRI and behavioral studies.
Fluoxetine and vortioxetine reverse depressive-like phenotype and memory deficits induced by amyloid-β (1-42) oligomers in mice: implication of transforming growth factor-β1 and oxidative stress
A long-term treatment with antidepressants reduces the risk to develop AD and different second-generation antidepressants such as selective serotonin reuptake inhibitors (SSRIs) are currently studied for their neuroprotective properties in AD. An impairment of neurotrophic factors signaling seems to be a common pathophysiological event in depression and AD. In particular a deficit of transforming growth factor-β1 (TGF-β1) and increased oxidative stress have been found both in depression and AD. In the present work the SSRI fluoxetine and the new multimodal antidepressant vortioxetine were tested for their ability to prevent memory deficits and depressive-like phenotype in a non-transgenic mouse model of AD (i.c.v. Aβ1-42 injection) by rescue of TGF-β1 signaling. The same drugs were also tested for their ability to modulate the expression of pro-oxidant genes as well as of genes related to the antioxidant machinery.